BMS 767778

Drug Profile

BMS 767778

Alternative Names: BMS-767778

Latest Information Update: 23 Apr 2013

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class 2 ring heterocyclic compounds; Antihyperglycaemics; Pyridines; Pyrroles
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 07 Apr 2013 Pharmacodynamics data presented at the 245th National Meeting of the American Chemical Society (ACS-2013)
  • 04 Sep 2008 Phase-I clinical trials in Type-2 diabetes mellitus in Canada (PO)
  • 04 Sep 2008 Bristol-Myers Squibb initiates enrolment in a phase I trial for Type-2 diabetes mellitus in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top